Generation of transgenic <i>R26-AKT1</i>^<i>E17K</i> mouse.

<p><b>A.</b> Schematic representation of the targeting construct used for the conditional knock-in in the <i>R26</i> locus. The human <i>AKT1</i>^<i>E17K</i> cDNA preceded by a loxP-flanked transcriptional stop cassette, was recombined into the R26 locus. Cre-mediated removal of the stop cassette links Rosa26 exon 1 to the exogenous cDNA allowing expression of the transgene. <b>B.</b> Southern blot of EcoRV digested genomic DNA derived from mESCs transfected with the targeting construct carrying mutant AKT1. Lane 1: DNA from non-targeted mESCs, lane 2 and 3: DNA from DNA from two different <i>R26-AKT1</i>^<i>E17K</i> mESCs strains. Endogenous allele corresponds to the 11.5 kb band (<i>WT</i>); mutant allele corresponds to the 4.3 kb band (<i>REC</i>). <b>C.</b> Relative mRNA expression of human AKT1^E17K by Q-RT-PCR in targeted mESCs and in the corresponding cells transfected with the Flp (pFlpE-IRES-Puro) or Cre recombinase (pCre-IRES-Puro). Data are from replicate experiments as the mean±SD. ***p<0.001. <b>D</b>. Genotype analysis by PCR on tail-tip DNA of genetically modified mice as indicated.</p

Mutant AKT1^E17K accelerates tumor formation induced by chemical carcinogens.

<p><b>A.</b> Lung tumor multiplicity in <i>R26-AKT1</i>^<i>E17K</i> infected with Ad-Cre (6 and 9 months after the treatment, respectively). Each point represents one mouse; bars represent means ± SD. **p<0.01, *p<0.05. <b>B.</b> Diameter of lung tumors generated by urethane in <i>R26-AKT1</i>^<i>E17K</i> mice treated with increasing doses of Ad-Cre. Bars represent mean diameter of tumor ±SD. *p<0.05. <b>C, D.</b> Representative H&E staining of lung lesions developed in <i>R26-AKT1</i>^<i>E17K</i> mice treated with solvent or Ad-Cre, as indicated, 9 months after urethane administration. <b>E, F.</b> Phosporylated AKT staining of lung lesions developed in <i>R26-AKT1</i>^<i>E17K</i> mice treated with solvent or Ad-Cre, as indicated, 9 months after urethane administration. Magnification as indicated.</p

Immunostaining analysis of <i>R26-AKT1</i>^<i>E17K</i> mice.

<p>pAKT immunostaining of lung tissues from <i>R26-AKT1</i>^<i>E17K</i> mice treated with solvent alone (A) or infected with Ad-Cre after 9 and 18 months from infection, respectively (B, C).</p

Phenotypic analysis of <i>R26-AKT1</i>^<i>E17K</i><i>; Ttf1-Cre</i> mice.

<p><b>A</b>. PCR analysis of lung DNA from <i>R26-AKT1</i>^<i>E17K</i><i>; Ttf1-Cre</i> and control littermates. ∆Stop tpA: lox-P flanked transcription termination stop signal. <b>B.</b> Relative mRNA expression of human AKT1 by Q-RT-PCR on RNA of lungs from <i>R26; Ttf1-Cre</i>, <i>R26-AKT1</i>^<i>E17K</i><i>; Ttf1-Cre</i>. Data are presented from replicate analysis as the mean±SD. <b>C.</b> Representative immunoblot analysis of pAKT, total AKT1 and downstream signalling proteins in total protein extracts from whole lungs of <i>R26; Ttf1-Cre</i> and <i>R26-AKT1</i>^<i>E17K</i><i>; Ttf1-Cre</i> mice, respectively. <b>D-E.</b> Representative H&E staining of lungs from <i>R26;Ttf1-Cre</i> and <i>R26-AKT1</i>^<i>E17K</i><i>; Ttf1-Cre</i>, respectively. Magnification as indicated. <b>F-G.</b> Representative pAKT staining of lungs from <i>R26;Nkx2</i>.<i>1-Cre</i> and <i>R26-AKT1</i>^<i>E17K</i><i>;Nkx2</i>.<i>1-Cre</i>, respectively. Magnification as indicated.</p

Phenotypic analysis of <i>R26-AKT1</i>^<i>E17K</i> mice infected with Ad-Cre.

<p><b>A-D.</b> Representative H&E staining of lung epithelium of <i>R26-AKT1</i>^<i>E17K</i> mice treated with solvent alone (not infected) or infected with Ad-Cre (9 and 18 month-old, respectively). Magnification as indicated.</p

Indirect immunofluorescence for CC10 and SP-C in mouse lung.

<p>Representative immunofluorescence images of lung sections from <i>R26-AKT1</i>^<i>E17K</i> infected with Ad-Cre, treated with urethane or both. Panels A–C show lung sections analyzed using antibodies to CC10. Panels D–F show lung sections analyzed using antibodies to SP-C. Nuclei were stained with DAPI and are shown in blue. Magnification, 60X.</p

Additional file 1: of Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

Figure S1. Correlation of platinum sensitivity status with survival. Kaplan Meier curves of EOC patients grouped according to platinum sensitive (PS) or resistant (PR) disease. Patients with a platinum sensitive ovarian cancer presents a significant longer survival thus confirming the reliability of the sample. (JPG 182 kb